IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer
Li, You-quan; Shi, An-hui; Li, Fu-hai; Yu, Rong; Zhu, Guang-ying
关键词Non-small-cell Lung Cancer Concurrent Chemoradiotherapy Cisplatin Docetaxel Toxicity
刊名CHINESE JOURNAL OF CANCER RESEARCH
2011-06-01
DOI10.1007/s11670-011-0129-9
23期:2页:129-133
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]THORACIC RADIOTHERAPY ; FOLLOW-UP ; CHEMOTHERAPY ; TRIAL ; CARBOPLATIN ; PACLITAXEL ; SURVIVAL
英文摘要

To evaluate the maximum tolerated dose (MTD) of docetaxel (DCT) and cisplatin (DDP) concurrently with three dimensional (3D) conformal radiotherapy or IMRT for patients with locally advanced non-small cell lung cancer (stage IIIa and IIIb) after 2-4 cycles of induction chemotherapy.

Fourteen patients with histological/cytological proven stage III non-small-cell lung cancer were eligible. 3D or IMRT radiotherapy (60-70Gy in 30-35 fractions, 6-7weeks, 2 Gy/fraction) was delivered concurrently with cisplatin and docetaxel, 2 cycles during concurrent chemoradiotherapy (CCRT). The level I dosage was composed of 56 mg/m(2) DCT, on day 1 and 28mg/m(2) DDP, on day 1 and day 2. The level II was composed of 60 mg/m(2) DCT, on day 1 and 30 mg/m(2) DDP, on day 1 and day 2. The level III was composed of 64 mg/m(2) DCT, on day 1 and 32 mg/m(2) DDP, on day 1 and day 2.

Fourteen patients were allocated and finished concurrent chemoradiotherapy. The dose-limiting neutropenia was at the dose Level III (64 mg/m(2)) and occurred in 2 of 5 patients. No dose limiting non-hematologic or hematologic toxicity occurred in the other patients.

Patients with locally advanced non-small cell lung cancer may tolerate 60mg/m(2) docetaxel and 60mg/m(2) cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.

语种英语
WOS记录号WOS:000290804600008
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52266
专题北京大学临床肿瘤学院
北京大学临床肿瘤学院_肿瘤放疗科
作者单位Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Li, You-quan,Shi, An-hui,Li, Fu-hai,et al. Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2011,23(2):129-133.
APA Li, You-quan,Shi, An-hui,Li, Fu-hai,Yu, Rong,&Zhu, Guang-ying.(2011).Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer.CHINESE JOURNAL OF CANCER RESEARCH,23(2),129-133.
MLA Li, You-quan,et al."Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer".CHINESE JOURNAL OF CANCER RESEARCH 23.2(2011):129-133.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, You-quan]的文章
[Shi, An-hui]的文章
[Li, Fu-hai]的文章
百度学术
百度学术中相似的文章
[Li, You-quan]的文章
[Shi, An-hui]的文章
[Li, Fu-hai]的文章
必应学术
必应学术中相似的文章
[Li, You-quan]的文章
[Shi, An-hui]的文章
[Li, Fu-hai]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。